Brief: Tiziana Life Sciences To File Alzheimer’S Ind For Intranasal Foralumab In Q2 2023
20/04/2023 13:15
April 20 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES TO FILE ALZHEIMER’S IND FOR
INTRANASAL
FORALUMAB IN Q2 2023
* TIZIANA LIFE SCIENCES LTD - APPLICATION FOR $3M OF
NON-DILUTIVE
FUNDING FOR PHASE 2A ALZHEIMER'S TRIAL WILL BE SUBMITTED IN Q2
2023
Source text for Eikon: ID:nGNXmvlY5
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study